Screening for anxiety and depression in people with psoriasis: a cross-sectional study in a tertiary referral setting

Abstract

Summary Background National Institute for Health and Care Excellence guidance recommends assessment of psychological and social well‐being in people with psoriasis. Objectives To screen systematically for depression and anxiety in patients with psoriasis in routine clinical practice and to identify at‐risk groups for psychiatric morbidity. Methods Consecutive patients attending a single, tertiary centre over a 10‐month period were invited to complete the Patient Health Questionnaire Depression Scale (PHQ‐9), Generalized Anxiety Disorder Scale (GAD‐7) and Dermatology Life Quality Index (DLQI) as part of IMPARTS: Integrating Mental and Physical Healthcare: Research, Training and Services. Information on demographics, treatment and clinical disease severity was collated from electronic patient records. Regression models were used to identify at‐risk groups for psychiatric morbidity. Results Of 607 patients included (56·2% on biologics), 9·9% (95% confidence interval 7·5–12·3%) screened positive for major depressive disorder (MDD) and 13·1% (79/604) (95% confidence interval 10·4–15·8%) for generalized anxiety disorder (GAD; GAD‐7 score > 9). Suicidal ideation was reported in 35% of those with MDD; DLQI was < 10 in 38·3% and 45·6% cases of MDD and GAD, respectively. After adjusting for covariates, the risk of MDD or GAD was significantly higher in women and those with severe clinical disease, psoriatic arthritis and previous depression/anxiety. The risk of GAD was significantly increased with Asian ethnicity and use of topical treatments only. Conclusions Systematic screening for anxiety and depression identifies clinically important levels of depression and anxiety that may be missed using DLQI data alone. Women and those with severe disease, psoriatic arthritis and/or a prior history of psychiatric morbidity may be at particular risk.

Anxiety and depression in patients with moderate‐to‐severe psoriasis and comparison of change from baseline after treatment with guselkumab vs. adalimumab: results from the Phase 3 VOYAGE 2 study

“…Psoriasis, a chronic immune‐mediated disorder, not only affects skin‐related symptoms and signs, but can also negatively impact a patient's quality of life . The burden of psoriasis has even been categorized as a cumulative disability, which can negatively impact a patient throughout their lifetime .…”

The association between the socioeconomic status and anxiety–depression comorbidity in patients with psoriasis: a nationwide population‐based study

“…Defined as a chronic, inflammatory skin disease causing scaly lesions on the body surface, psoriasis is known to affect not only patients’ mental health but also adversely impact physical function, work and social life . Studies indicate that the risk of developing a major depressive disorder or a generalized anxiety disorder is significantly higher in women with severe clinical disease of psoriasis . These effects were found to be more pronounced among adult psoriasis patients with pre‐adult onset, with age serving as a moderator of the effect of psoriasis on the degree of psychological impediment .…”

Treatment patterns, unmet need, and impact on patient-reported outcomes of psoriatic arthritis in the United States and Europe

“…Patients with PsO also have higher levels of anxiety and depression, with the risk of these comorbidities further increased when suffering from both PsO and PsA [30, 31]. …”